Quanterix

Quanterix is a company that has developed a platform that performs single molecule analysis. The company was founded by David R. Walt in 2007, in Billerica, Massachusetts, United States.

The company offers their solution, Simoa, to provide single-molecule analysis to clinical diagnostics, drug development, and life science research. Quanterix is interested in deploying their technologies for fields such as oncology, neurology, cardiology, inflammatory, infectious diseases.

Quanterix is developing the ability to detect oncology biomarkers in order to create new options for diagnostics and treatments. Simoa is able to monitor cancer risk, identify early stage cancers, and predict disease outcomes.

For neurological issues, Simoa is able to detect neurological biomarkers associated with brain injury and disease during early stages, in blood, serum, or plasma without invasive procedures. The company is developing strategies for neurodegeneration, neuroinflammation, traumatic brain injuries, and multiple sclerosis.

Some of the cardiac biomarkers that Simoa can detect allow the platform to predict cardiovascular events such as heart failure, end-stage kidney disease, and more.

In the use case of inflammatory issues, Simoa can measure inflammatory and anti-inflammatory molecules in both serum and plasma. The product has been used for research on inflammatory assays such as C-Peptide, Cathepsin S, Alpha2-macroglobulin, Chemokine Panel, and more.

Simoa has been used to fight against and treat COVID-19, as it is able to measure cytokine levels and profiles in both critical and non-critical, and even asymptomatic patients.